Departments of Pediatric Surgery, Selcuk University, Faculty of Medicine, Konya, Turkey.
Departments of Pediatric Hematology and Oncology, Selcuk University, Faculty of Medicine, Konya, Turkey.
Niger J Clin Pract. 2023 Aug;26(8):1165-1170. doi: 10.4103/njcp.njcp_99_23.
Lymphatic malformations (LMs) are rare congenital anomalies. The traditional treatment is surgical excision, but intralesional sclerosing agent injection is also preferred as the first-choice treatment because of postoperative frequent recurrences, poor cosmetic results, and high complication rate. We aimed to evaluate the efficacy of sclerosing agent injection used in the treatment of LMs in children.
We retrospectively analyzed the children who were treated for LM between January 2011 and January 2022. The lesion sizes of the patients who were injected with sclerosant (Bleomycin) under sedation anesthesia, measured by ultrasound before and after the treatment, were recorded, and the difference between them was statistically evaluated.
Fifteen patients were retrospectively analyzed. The mean age was 45.2 ± 14.1 months. Of these, ten (66.6%) were male and five (33.3%) were female (F/M = 1/2). The mean age of male patients was 55 ± 20.1 months; the mean age of female patients was 25.8 ± 11. Seven patients had a single dose, two had twice, and six had three and more. The mean measurable size of macrocystic lesions before treatment was 55.2 ± 28.4 mm; after treatment, it was 23.8 ± 18.2 mm. Although no measurable shrinkage was detected in microcystic lesions, it was observed that the lesion shrank to allow surgical resection. With the statistical analysis, it was seen that there was a statistically significant difference between the dimensions before and after the treatment (P < 0.05) and the sclerosant injection had a great effect on the treatment (R: 0.89).
Intralesional injection of bleomycin is less effective for microcystic or mixed-type LMs, but provides an effective reduction for a safe surgical procedure. It is an effective treatment for macrocystic lesions.
淋巴管畸形（LM）是一种罕见的先天性异常。传统的治疗方法是手术切除，但由于术后复发频繁、美容效果差和并发症发生率高，腔内硬化剂注射也被优先作为首选治疗方法。我们旨在评估硬化剂注射在儿童 LM 治疗中的疗效。
我们回顾性分析了 2011 年 1 月至 2022 年 1 月期间接受 LM 治疗的儿童患者。记录了在镇静麻醉下注入硬化剂（平阳霉素）的患者的病变大小，通过超声治疗前后进行测量，并对其差异进行了统计学评估。
共回顾性分析了 15 例患者。平均年龄为 45.2 ± 14.1 个月。其中，男性 10 例（66.6%），女性 5 例（33.3%）（F/M=1/2）。男性患者的平均年龄为 55 ± 20.1 岁；女性患者的平均年龄为 25.8 ± 11 岁。7 例患者单次注射，2 例患者两次注射，6 例患者三次及以上注射。治疗前大囊型病变的平均可测量大小为 55.2 ± 28.4mm；治疗后为 23.8 ± 18.2mm。虽然微囊型病变未检测到可测量的缩小，但观察到病变缩小，以便进行手术切除。通过统计分析，发现治疗前后的尺寸差异具有统计学意义（P<0.05），硬化剂注射对治疗有很大影响（R：0.89）。
平阳霉素腔内注射对微囊型或混合型 LM 的效果较差，但可为安全的手术程序提供有效的减少。它是大囊型病变的有效治疗方法。
